MAZE
Maze Therapeutics Inc.

32
Loading...
Loading...
News
all
press releases
News Placeholder
Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened
The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.
Stocktwits·21h ago
News Placeholder
Maze Therapeutics receives positive ratings following recent IPO
Investing.com -- Maze Therapeutics Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.
investing.com·7mo ago

Latest MAZE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.